This manuscript describes how TRPblue’s lead compound (TB16-8) was discovered by increasing the TRPV4 potency of a known tool compound which resulted in the ability for this novel compound to inhibit TRPA1 as well. This novel dual-channel blocker inhibited inflammation and pain-associated behavior in a model of acute pancreatitis – known to also rely on TRPV4 and TRPA1.
